Bank of America’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Bank of America’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-34,400	Closed	-$461K	–	7547
2019 Q1	$461K	Hold	34,400	–	–	﹤0.01%	5061
2018 Q4	$320K	Buy	34,400 +24,400	+244%	+$290K	﹤0.01%	5217
2018 Q3	$139K	Sell	10,000 -5,000	-33%	-$74.4K	﹤0.01%	5698
2018 Q2	$237K	Hold	15,000	–	–	﹤0.01%	5318
2018 Q1	$258K	Sell	15,000 -300	-2%	-$5.85K	﹤0.01%	5227
2017 Q4	$335K	Buy	15,300 +10,000	+189%	+$322K	﹤0.01%	5158
2017 Q3	$217K	Buy	+5,300	New	+$166K	﹤0.01%	5346

Bank of America's FPRX Position: Q2 2021 in Review

Bank of America sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 95,126 shares — an estimated $3.58M sold.

Bank of America first reported a position in FPRX in Q1 2014 and held it in 28 quarters. The position peaked at $3.58M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

Bank of America reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Bank of America sold 95,126 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $3.58M.
Bank of America first reported a position in Five Prime Therapeutics, Inc. in Q1 2014 and held it in 28 quarters.
Bank of America's Five Prime Therapeutics, Inc. position peaked at $3.58M in Q1 2021.
0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Bank of America's 13F filing for Q2 2021, filed 16 Aug 2021.